- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00558636
A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
2 de diciembre de 2013 actualizado por: Bayer
A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study conducted in Asia-Pacific was to evaluate the efficacy and safety of Sorafenib in combination with paclitaxel and carboplatin versus placebo in combination with paclitaxel and carboplatin for chemonaive patients with unresectable stage IIIB (with effusion) or stage IV NSCLC.
However, as indicated below, the study was terminated prematurely when the results from Study 11961 (NCT00300885), an earlier Phase 3 study of similar design in subjects with advanced NSCLC, showed an overall lack of efficacy and increased mortality in subjects with squamous subtype.
The data available is presented as descriptive analyses, due to the limitations of implementing the statistical analysis plan.
Descripción general del estudio
Estado
Terminado
Condiciones
Intervención / Tratamiento
Descripción detallada
The study was terminated early when the results from Study 11961 (NCT00300885), an earlier Phase 3 study evaluating the effects of Sorafenib in combination with paclitaxel and carboplatin in subjects with advanced NSCLC, showed an overall lack of efficacy of Sorafenib in combination with paclitaxel and carboplatin in NSCLC and increased mortality in subjects with squamous subtype.
Tipo de estudio
Intervencionista
Inscripción (Actual)
91
Fase
- Fase 3
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
-
Gyeonggi-do, Corea, república de, 410-769
-
Seoul, Corea, república de, 136-705
-
-
-
-
-
New- Delhi, India, 110008
-
-
Maharashtra
-
Mumbai, Maharashtra, India, 400012
-
-
-
-
-
Beijing, Porcelana, 100730
-
Beijing, Porcelana, 100021
-
Beijing, Porcelana, 100142
-
Chongqing, Porcelana, 400038
-
Shanghai, Porcelana, 200032
-
Shanghai, Porcelana, 200433
-
-
Guangdong
-
Guangzhou, Guangdong, Porcelana, 510060
-
Guangzhou, Guangdong, Porcelana, 510515
-
-
Hong Kong
-
Shatin, Hong Kong, Porcelana
-
-
Jiangsu
-
Nanjing, Jiangsu, Porcelana, 210003
-
-
Zhejiang
-
Hangzhou, Zhejiang, Porcelana, 310016
-
Hangzhou, Zhejiang, Porcelana, (310022),
-
-
-
-
-
Singapore, Singapur, 119228
-
Singapore, Singapur, 169610
-
-
-
-
-
Bangkok, Tailandia
-
Bangkok, Tailandia, 10330
-
-
-
-
-
Changhua, Taiwán, 500
-
Taipei, Taiwán, 100
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años y mayores (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Descripción
Inclusion Criteria:
- Stage IIIB (with cytologically confirmed malignant pleural or pericardial effusion) or Stage IV histological or cytological confirmation of NSCLC (thoracentesis or pericardiocentesis is not necessary if a biopsy of the original tumor is available to confirm diagnosis of NSCLC)
- Patients must have measurable disease according to response evaluation criteria in solid tumors (RECIST) criteria
- Prior local radiotherapy is allowed if it is completed at least 3 weeks prior to the first dose of study drug, but the lesion which undergo RECIST assessment should not be in the field of the prior radiation
- Prior surgery is allowed if it is performed at least 4 weeks prior to the first dose of study drug
- 18 years and above
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Life expectancy of at least 12 weeks
- Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to start of first dose:
- Hemoglobin 9.0 g/dl
- Absolute neutrophil count (ANC) 1,500/mm3
- Platelet count 100,000/mm3
- Total bilirubin < 1.5 times the upper limit of normal
- alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x upper limit of normal (< 5 x upper limit of normal for patients with liver involvement)
- international normalized ratio (INR) < 1.5 and activated or adjusted partial thromboplastin time (APTT) within normal limits (1.2 times the lower limit of normal (LLN) to 1.2 times the upper limit of normal (ULN))
- Creatinine </= 1.5 times the upper limit of normal
- Ability to understand and the willingness to sign a written informed consent. A signed informed consent must be obtained prior to any study specific procedures
Exclusion Criteria:
- Any prior systemic anticancer therapy including cytotoxic therapy, targeted agents, experimental therapy, adjuvant, or neo-adjuvant therapy for any current or prior diagnosis of NSCLC
- Cardiac disease: Congestive heart failure > class II New York Heart Association (NYHA). Patients must not have unstable angina (anginal symptoms at rest) or new-onset angina (began within the last 3 months) or myocardial infarction within the past 6 months
- Known brain metastasis. Patients with neurological symptoms should undergo at Computed Tomography (CT) scan/Magnetic Resonance Imaging (MRI) of the brain to exclude brain metastasis
- Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy
- Uncontrolled hypertension defined as systolic blood pressure > 150 mm Hg or diastolic pressure > 90 mm Hg, despite optimal medical management
- Known human immunodeficiency virus (HIV) infection
- Active clinically serious infections > Common Terminology Criteria for Adverse Events (CTCAE) Grade 2
- Thrombotic or embolic events such as cerebrovascular accident including transient ischemic attacks within the past 6 months
- Pulmonary hemorrhage/bleeding event > CTCAE Grade 2 within 4 weeks of first dose of study drug
- Any other hemorrhage/bleeding event > CTCAE Grade 3 within 4 weeks of first dose of study drug
- Serious, non-healing wound, ulcer, or bone fracture
- Evidence or history of bleeding diathesis or coagulopathy
- Major surgery, open biopsy or significant traumatic injury within 4 weeks of first dose of study drug
- Therapeutic anticoagulation with vitamin K antagonists such as warfarin, or with heparins or heparinoids. Low dose warfarin (1 mg daily, oral) is permitted if the INR remains < 1.5. Low-dose aspirin is permitted
- Known or suspected allergy to sorafenib or any agent given in the course of this trial
- Cancer other than NSCLC within 5 years prior to start of study treatment, EXCEPT cervical cancer in-situ, treated basal cell carcinoma, or superficial bladder tumors
- Concurrent cancer that is distinct in primary site or histology from NSCLC
- Substance abuse, medical, psychological or social conditions that may interfere with the patients participation in the study or evaluation of the study results
- Any condition that impairs patients ability to swallow whole pills
- Any malabsorption condition
- Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment
- Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation, including the 30 days period after last study drug dosing. The investigator should advise the patient how to achieve an adequate contraception
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Sorafenib + Paclitaxel + Carboplatin
Chemotherapy plus Multi Kinase Inhibitor: Sorafenib Group - Sorafenib (Nexavar, BAY43-9006), [400 mg, (2 tablets x 200 mg each) orally, twice daily] on Study Days 2-19 and paclitaxel (175 mg/m^2, intravenous (IV), over 2.5 to 4 hours) and carboplatin (area under the curve (AUC) =5, IV for 15 to 60 minutes) on Study Day 1.
The cycle duration will be 21 days.
|
Chemotherapy plus Multi Kinase Inhibitor: Sorafenib Group - Sorafenib (Nexavar, BAY43-9006), [400 mg, (2 tablets x 200 mg each) orally, twice daily] on Study Days 2-19 and paclitaxel (175 mg/m^2, intravenous (IV), over 2.5 to 4 hours) and carboplatin (area under the curve (AUC) =5, IV for 15 to 60 minutes) on Study Day 1.
The cycle duration will be 21 days.
|
Comparador de placebos: Placebo + Paclitaxel + Carboplatin
Chemotherapy + Placebo: Placebo Group - Placebo (2 tablets twice daily, orally) on Study Days 2-19 and paclitaxel (175 mg/m^2 IV, over 2.5 to 4 hours) and carboplatin (AUC=5 IV, for 15 to 60 minutes) on Study Day 1.
The cycle duration will be 21 days
|
Chemotherapy + Placebo: Placebo Group - Placebo (2 tablets twice daily, orally) on Study Days 2-19 and paclitaxel (175 mg/m^2 IV, over 2.5 to 4 hours) and carboplatin (AUC=5 IV, for 15 to 60 minutes) on Study Day 1.
The cycle duration will be 21 days
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Progression Free Survival
Periodo de tiempo: Up to 5 months after randomization of the first patient
|
Progression free survival (PFS) is the time (days) from date of randomization to date of first observed disease progression (radiological or clinical, whichever was earlier) or death due to any cause, if death occurred before progression was documented.
Since the study was terminated early and 89% of subjects' data were censored, only the number of PFS events (Failed [progressed or died before progression]) is reported, not the usual measure "number of days".
|
Up to 5 months after randomization of the first patient
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Overall Survival (OS)
Periodo de tiempo: Up to 5 months after randomization of the first patient
|
Overall survival is the number of days from the date of randomization to the date of death due to any cause.
Subjects alive at the time of analysis were censored at their last date of follow-up.
Since the study was terminated early and 89% of subjects' data were censored, only the number of subjects who Failed (died) or were Censored is reported, not the usual measure "number of days".
|
Up to 5 months after randomization of the first patient
|
Best Tumor Response (Number of Responses Per Category) According to Response Evaluation Criteria in Solid Tumors (RECIST)
Periodo de tiempo: Best tumor response assessed every 6 weeks by investigator during treatment up to 5 months after randomization of the first patient.
|
Complete response (CR): Disappearance of all target lesions (TL).
Partial response (PR): At least 30% decrease in sum of the largest diameter (LD) of TLs, taking baseline sum as reference.
Stable disease (SD): No change in tumor size.
Progressive disease (PD): At least a 20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since treatment started, or the appearance of 1 or more new lesions.
|
Best tumor response assessed every 6 weeks by investigator during treatment up to 5 months after randomization of the first patient.
|
Duration of Response
Periodo de tiempo: Time from first documented objective response (complete response or partial response) to disease progression or death, or to last tumor assessment if censored, up to 5 months after randomization of the first patient.
|
Duration of response (PR or better) was defined as the time from the first documented objective PR or CR, whichever was noted earlier, to disease progression or death (if death occurred before progression was documented).
Since only 4 subjects had a response, the duration of response was not calculated.
|
Time from first documented objective response (complete response or partial response) to disease progression or death, or to last tumor assessment if censored, up to 5 months after randomization of the first patient.
|
Change From Baseline of Lung Cancer Symptoms (LCS) Score Assessed at Each Treatment Cycle (21 Days Per Cycle) Starting With Cycle 2
Periodo de tiempo: Change from baseline of LCS score assessed at each treatment cycle starting with Cycle 2 (Cycles 2, 3, 4, 5, 6, 7; 21 days per cycle) up to 5 months after randomization of the first patient.
|
The LCS is a validated instrument for determining treatment impact on lung symptoms.
The LCS consists of 7 questions with 5 responses ranging from "not at all" to "very much".
The LCS total score ranges from 0 to 28.
Lower scores reflect greater lung cancer symptoms.
|
Change from baseline of LCS score assessed at each treatment cycle starting with Cycle 2 (Cycles 2, 3, 4, 5, 6, 7; 21 days per cycle) up to 5 months after randomization of the first patient.
|
Change From Baseline of Health-Related Quality of Life (HRQoL) Score Assessed at Treatment Cycle 3 and Cycle 5
Periodo de tiempo: Change from baseline of HRQoL score assessed (at treatment Cycle 3 and Cycles 5 [21 days per cycle]) up to 5 months after randomization of the first patient.
|
HRQoL was assessed with the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire, a validated instrument for determining lung cancer HRQoL.
The 36-item questionnaire includes 4 domains: Physical, functional, emotional, and social/family well-being, and a lung cancer-specific subscale.
The FACT-L total score ranges from 1 to 136.
Lower scores demonstrate impaired HRQoL.
|
Change from baseline of HRQoL score assessed (at treatment Cycle 3 and Cycles 5 [21 days per cycle]) up to 5 months after randomization of the first patient.
|
Change From Baseline of Health-Related Quality of Life (HRQoL) Score Assessed at Treatment Cycle 7
Periodo de tiempo: Change from baseline of HRQoL score assessed (at treatment Cycle 7 [21 days per cycle]) up to 5 months after randomization of the first patient.
|
HRQoL was assessed with the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire, a validated instrument for determining lung cancer HRQoL.
The 36-item questionnaire includes 4 domains: Physical, functional, emotional, and social/family well-being, and a lung cancer-specific subscale.
The FACT-L total score ranges from 1 to 136.
Lower scores demonstrate impaired HRQoL.
|
Change from baseline of HRQoL score assessed (at treatment Cycle 7 [21 days per cycle]) up to 5 months after randomization of the first patient.
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio
1 de septiembre de 2007
Finalización primaria (Actual)
1 de mayo de 2008
Finalización del estudio (Actual)
1 de mayo de 2008
Fechas de registro del estudio
Enviado por primera vez
9 de noviembre de 2007
Primero enviado que cumplió con los criterios de control de calidad
14 de noviembre de 2007
Publicado por primera vez (Estimar)
15 de noviembre de 2007
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
27 de diciembre de 2013
Última actualización enviada que cumplió con los criterios de control de calidad
2 de diciembre de 2013
Última verificación
1 de diciembre de 2013
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades de las vías respiratorias
- Neoplasias
- Enfermedades pulmonares
- Neoplasias por sitio
- Neoplasias de las vías respiratorias
- Neoplasias torácicas
- Carcinoma Broncogénico
- Neoplasias Bronquiales
- Neoplasias Pulmonares
- Carcinoma de pulmón de células no pequeñas
- Mecanismos moleculares de acción farmacológica
- Inhibidores de enzimas
- Agentes antineoplásicos
- Moduladores de tubulina
- Agentes antimitóticos
- Moduladores de mitosis
- Agentes antineoplásicos, fitogénicos
- Inhibidores de la proteína quinasa
- Carboplatino
- Paclitaxel
- Sorafenib
- Paclitaxel unido a albúmina
Otros números de identificación del estudio
- 12621
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Carcinoma de pulmón de células no pequeñas
-
Adelphi Values LLCBlueprint Medicines CorporationTerminadoLeucemia de mastocitos (LCM) | Mastocitosis Sistémica Agresiva (ASM) | SM w Asoc Clonal Hema Non-mast Cell Linage Disease (SM-AHNMD) | Mastocitosis sistémica latente (MSS) | Mastocitosis Sistémica Indolente (ISM) Subgrupo ISM Completamente ReclutadoEstados Unidos
Ensayos clínicos sobre Sorafenib + Paclitaxel + Carboplatin
-
Gesellschaft fur Medizinische Innovation - Hamatologie...iOMEDICO AGTerminadoCáncer de mama metastásicoAlemania
-
BayerTerminadoCarcinoma de pulmón de células no pequeñasBélgica, Italia, España, Hong Kong, Estados Unidos, Alemania, Reino Unido, Chile, Taiwán, Australia, Canadá, Argentina, Puerto Rico, Francia, Polonia, Federación Rusa, Suecia, Hungría, Países Bajos, Brasil, Corea, república de
-
National Cancer Institute (NCI)TerminadoMelanoma de cuerpo ciliar y coroides, tamaño mediano/grande | Iris Melanoma | Melanoma intraocular metastásico | Melanoma intraocular recurrente | Melanoma de extensión extraocularEstados Unidos
-
Northwestern UniversityAmgenDesconocidoCáncer de mamaEstados Unidos
-
University of Texas Southwestern Medical CenterRetirado
-
BayerAmgenTerminadoMelanomaEstados Unidos, Canadá, Alemania, Francia, Reino Unido, Australia, Países Bajos
-
National Cancer Institute (NCI)TerminadoCarcinoma de trompa de Falopio recidivante | Carcinoma de ovario recurrente | Carcinoma peritoneal primario recidivanteEstados Unidos
-
Mt. Sinai Medical Center, MiamiBayer; Celgene CorporationTerminadoMelanoma malignoEstados Unidos
-
Veeda OncologyBayer; Celgene CorporationTerminadoCáncer de mamaEstados Unidos
-
BayerAmgenTerminado